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Background: Abnormal expression of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5, also called as
survivin), a novel member of the inhibitor of apoptosis protein (IAP) family, has implications in many types of cancer
and is considered as a new therapeutic target. We suppose that genetic variant rs9904341 in the 5′ UTR region of
survivin gene may be associated with the development and progression of prostate cancer (PCa) in Chinese
population.
Methods: TaqMan assay method was used to genotype the polymorphism in the hospital-based case–control
analysis of 665 patients with PCa and 710 age-matched cancer-free controls. The genetic associations with the
occurrence and progression of PCa were calculated by logistic regression.
Results: Our results indicated that compared with GG genotypes, there was a statistically significant increased risk
of PCa associated with those with CC genotypes [odds ratios (ORs) = 1.57, 95%confidence intervals (CIs) = 1.17-2.13,
P = 0.004]. Moreover, stratification analysis revealed that the association was more pronounced in subgroups of
nondrinkers, nonsmokers and those without a family history of cancer (all P < 0.05). In addition, we observed that
PSA ≥ 20 was more frequent in patients carrying GC/CC genotypes than in those with a wild type genotype.
Conclusion: The functional survivin rs9904341 genetic variant may have a substantial influence on the PCa
susceptibility and evolution.
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Apoptosis is an essential genetic session which is neces-
sary for the proper development of an organism [1]. The
accumulation of virtually immortal cells,as the result of
apoptosis evasion, leads to many human disorders or even
cancer, which facilitates the acquisition of further molecu-
lar aberrations associated with biologically aggressive be-
haviors [2], As the apoptosis regulator containing four
exons separated by three introns spanning 14.7-kb,
surivivin (encoded by BIRC2) -is the smallest member of
inhibitory apoptosis protein (IAP) family [3,4]. It has* Correspondence: lijie203076@yahoo.com; drcjyin@gmail.com
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reproduction in any medium, provided the orattracted great attention for its unique, bifunctional role in
inhibiting apoptosis and cell cycle regulation [5,6]. Survivin
also regulates the apoptosis pathway by suppressing the
initiator caspase-9 and effector caspase-3 and caspase-7
[7-9]. Numerous studies have demonstrated that the reduc-
tion of survivin expression could bring with activated
caspase, spontaneous apoptosis, and inhibition of cell pro-
liferation and tumor growth, while the overexpression of
survivin appeared to be uniquely associated with the inhib-
ition of apoptosis [10]. Besides the anti-apoptotic proper-
ties, survivin expressed in a cell cycle-regulated manner
regulates the cell division. It is abundantly expressed in the
G2/M phase of the cell cycle, supporting the rapidly divid-
ing cell mechanism, [6,11]. Furthermore, animal studies
supported that survivin in conditional knockout mice hadtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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without catastrophic mitotic defects [12-16].
Prostate cancer (PCa) is a frequently-occurring disease
and is the second leading cause of cancer-related deaths
of Western males. An analysis of the incidence and mor-
tality of prostate cancer patients showed that approxi-
mately 217,730 new cases occurred and 32,050 deaths in
2010 in the U.S. [17]. The incidence rates of PCa in
China and America vary substantially, with a much
lower morbidity observed in China than in America.
However, the occurrence of PCa is rapidly increasing in
recent years in China [18].
Previously, accumulating evidences revealed that the ex-
pression of survivin was invariably up-regulated in human
cancers, associated with the resistance to radiation or
chemotherapy therapy, and poor prognosis [19-23].As to
PCa, several studies identified that the survivin, though
not normally expressed in the normal tissue and secretory
epithelial cells of the prostate [24], was strongly expressed
in PCa tissues and PCa cell lines at the level of RNA or
protein [25-29]. Moreover, substantial evidence indicated
that overexpression of survivin was related to the
established features of biologically aggressive PCa, such as
Gleason score and metastases [30-32]. As a whole,
survivin appears to be the most promising diagnostic and
prognostic markers in monitoring PCa.
Given the significant role of survivin in PCa, with bio-
logical, prognostic and therapeutic implications, we hy-
pothesized the functional single nucleotide polymorphisms
(SNPs) in the survivin gene in charge of expression or ac-
tivity might contribute to the susceptibility and survival of
PCa. Recently, the possible associations between the SNPs
in the survivin gene and various types of cancer have been
investigated in some prior studies [33-43]. Among them,
we paid more attention to one SNP −31 G/C (rs9904341)
in the promoter of survivin located at the cell cycle
dependent elements (CDE) and cell cycle homology re-
gions (CHR) repressor binding site [44]. Transcriptional
expression of survivin gene might be modulated by CDE/
CHR elements, as potentially implicated in imparting cell
cycle periodicity of expression in G2/M [6]. To verify this
hypothesis, we choose the genotype survivin rs9904341
polymorphism in our study of PCa in Chinese to identify if
genetic variants in survivin gene may result in the suscepti-
bility and progression of PCa.
Methods
Study population
Between September 2003 and January 2010, unrelated
male (n = 1375) self-described ethnic Han Chinese were
consecutively enrolled from the First Affiliated Hospital
of Nanjing Medical University, Nanjing, China. All of
the incident sporadic PCa cases (n = 665) were newly di-
agnosed, histopathologically confirmed and identified byreviewing the medical records that they had no prior
history of other cancers. Healthy controls (n = 710)
consisted of randomly-selected volunteers, and if they
were unrelated cases and age-matched were also
ascertained at the First Affiliated Hospital of Nanjing
Medical University. Before enrollment, peripheral blood
was obtained from every individual. A standard question-
naire through face-to-face interviews by trained inter-
viewers was made to collect demographic data and related
factors, including age, race, smoking history, alcohol intake,
and family history of cancer. The study was approved by
the Institutional Review Board of the Nanjing Medical
University, Nanjing, China. At recruitment, written in-
formed consent was obtained from all participants involved
in this study. Those subjects who smoked less one cigarette
per day and less one year over their lifetime were defined
as nonsmokers and the rest as smokers. Lighter or heavier
smokers were classified by WHO (World Health
Organization. Guidelines for he Conduct of Tobacco
Smoking Surveys for the General Population. Geneva,
Switzerland: World Health Organization; 1983. Document
WHO/SMO/83.4.). The participants who had pack-years
value (cigarettes per day/20) × (years smoked) < 20 were
considered as lighter smokers, the others (pack-years
value ≥ 20 pack-years) were considered as heavier smokers.
Those who drunk at least three times per week for more
than 6 months were defined as drinkers; otherwise, they
were considered as nondrinkers. Family history of cancer
was defined as any occurrence of cancer in first-degree
relatives (parents, siblings, or children). Disease stage was
determined by clinical stage (all cases were classified
according to the TNM classification system), Gleason score
and PSA value. Localized prostate cancer could be detect-
able clinically on examination, but had not proliferated out
of the prostate (T1-2N0M0). Advanced cancer meant the
cancer had spread through the prostatic capsule (T3-
4NXMX or TXN1MX or TXNXM1). The Gleason score was
estimated by pathologists in the hospital by using the
Gleason scoring system. Based on the EAU Guidelines on
Prostate Cancer and D’Amico’s Risk-Based management of
PCa, serum PSA value was classified into two groups
PSA > 20 ng/ml and PSA ≤ 20 ng/ml. The participation re-
sponse rates for both case and control subjects were > 85%.
DNA extraction and polymorphism genotyping
Genomic DNA was extracted from the peripheral blood
lymphocytes by using the conventional phenol-chloroform
method. SNP rs9904341 G >C in the promoter of survivin
gene was genotyped by the TaqMan MGB method with
ABI 7900HT Real Time PCR system (Applied Biosystems,
Foster city, CA) according to the manufacturer’s instruc-
tions. The primers and probes for rs9904341 G >C as fol-
lows: Forward primer, 5′- CGTGCGCTCCCGACAT-3′,
reverse primer, 5′- GATGCGGTGGTCCTTGAGAA-3′;
Table 1 Demographic and clinical variables of prostate
cancer cases and controls
Variables Cases (n = 665) Controls (n = 710) P *
n % n %
Age (years) (Mean ± SD) 71.4 ± 8.0 71.3 ± 7.4 0.833
≤ 71 310 46.6 355 50.0 0.210
> 71 355 53.4 355 50.0
Smoking status 0.005
Never 280 42.1 353 49.7
Ever 385 57.9 357 50.3
Pack-years of smoking <0.001
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C, 5′- HEX-TTGAATCGCCGGACC-MGB-3′. Amplifica-
tion was executed in 5 μL volumes in the 384-well plate,
for 2 min at 50°C,10 min at 95°C, followed by 45 cycles of
95°C for 15 sec and 60°C for 1 min . The ABI 7900HT Real
Time PCR system was adopted by the genotyping assay.
The SDS 2.4 software was used to automatically collect
and analyze the data and to subsequently generate the
genotype calls in a blind manner. Four negative controls in
each 384-well plate were used for quality control. Samples
making up more than 5% were randomly chosen for re-
peated genotyping, yielding a 100% concordant.0 281 42.3 353 49.7
0-20 127 19.1 177 24.9
>20 257 38.6 180 25.4
Drinking status 0.028
Never 468 70.4 537 75.6
Ever 197 29.6 173 24.4
Family history of cancer <0.001
No 536 80.6 655 92.2







>7 219 33.0Statistical analysis
Deviation of genotype distribution from the Hardy-
Weinberg equilibrium (HWE) for SNP rs9904341 amongst
controls was calculated by a goodness-of-fit χ2 test. The
student’s t-test (for continuous variables) or chi-square test
(for categorical variables) was performed to estimate the
differences in frequency distributions of selected demo-
graphic variables, selected variables, and frequencies of ge-
notypes between cases and controls. The associations
between survivin SNP rs9904341 and PCa risk were
assessed by computing odds ratios (ORs) and 95% confi-
dence intervals (CIs) from unconditional logistic regression
analysis with or without the adjustment for potential con-
founders. The P value < 0.05 was the criterion of statistical
significance, and all of the statistical tests were two sided.
All of the statistical analyses were dealt with SAS 9.1.3 soft-




* T-test for age distributions between the cases and controls; two-sided χ2 test
for others selected variables between the cases and controls.Results
Characteristics and clinical features of study population
The demographic characteristics and the clinical infor-
mation of 665 PCa patients and 710 controls in the
study were outlined in Table 1. Briefly, there was no
significant difference in terms of distribution of age be-
tween cases and controls (P = 0.833). However, in com-
parison with the controls, a crucially higher proportion of
the PCa patients smoked (57.9% versus 50.3%, P = 0.005),
drunk (29.6% versus 24.4%, P = 0.028) and had family his-
tory of cancer (19.4% versus 7.8%, P < 0.001). Specially, the
risk of cigarette addictives (> 20 pack-years) was 1.38
times more (95%CI, 1.20-1.61) than nonsmokers. For
40.9% of these 665 patients, PSA ≤ 20 ng/ml, and for the
rest, PSA were > 20 ng/ml. 390 of them were defined
as localized stage cancer, but only 275 of 710 had the
advanced stage cancer. When stratified according to
Gleason score, the percent of Gleason score < 7, = 7
and > 7 was 33.8%, 33.2% and 33.0%, respectively.
These variables were further adjusted with multivariate
logistic regression models.Genotype and allele frequencies of survivin
polymorphism in cases and controls
Genotyping call rate of rs9904341 was 99.25%. The
genotype and allele distributions of survivin SNP
rs9904341 between PCa cases and controls were sum-
marized in Table 2. The observed genotype frequencies
of SNP rs9904341 among the controls confirmed to
the HWE (P > 0.05). We observed that frequencies of
survivin genotypes were significantly different between
cases and controls (P = 0.014 and 0.003 for genotype
and allele, respectively), which principally derived from
discrepancy between wild-type GG (22.5% for cases
and 28.9% for controls) and variant-type CC (29.5% for
cases and 24.5 for controls). In the multivariate logistic
regression models with adjustments of age, smoking
status, drinking status, and family history of cancer,
our results indicated that CC genotype was associated
Table 2 Genotype and allele frequencies of the BIRC5 rs9904341 polymorphisms among the PCa cases and controls
Polymorphisms Cases (n = 665) Controls (n = 710) P * Adjusted OR
(95%CI) †n % n %
BIRC5 (rs9904341)
GG 150 22.5 205 28.9 0.014 1.00 (reference)
CG 319 48.0 331 46.6 0.038 1.32 (1.01-1.72)
CC 196 29.5 174 24.5 0.004 1.57 (1.17-2.13)
CG + CC 515 77.5 505 71.1 0.008 1.40 (1.09-1.80)
G 619 46.5 741 52.2 0.003 1.0 (reference)
C 711 53.5 679 47.8 1.12 (1.04-1.20)
P trend 0.004
* Two-sided χ2 test for the either genotype distributions or allele frequencies between the cases and controls.
† Adjusted for age, smoking status, drinking status, and family history of cancer in logistic regression model; 95% CI: 95% confidence interval; OR: odds ratio.
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with the GG genotype (OR = 1.57, 95% CI = 1.17-2.13).
Stratification analyses
Stratification analyses of age, smoking status, drinking
status, pack-years of smoking and family history of can-
cer with the genotypes of survivin rs9904341 poly-
morphism were presented in Table 3. We found that
individuals with CC/GC genotypes had a significantly in-
creased risk of PCa than those with GG genotype, which
appeared to be more evident in nonsmokers and non-
drinkers, and negative in those with family history of






Total 665/710 150/205 22.5/28.9
Age
≤ 71 310/355 66/98 21.3/27.6
> 71 355/355 84/107 23.7/30.1
Smoking status
Never 280/353 62/105 22.1/29.8
Ever 385/357 88/100 22.9/28.0
Pack-years of smoking
0-20 128/177 37/49 28.9/27.7
> 20 257/180 52/51 20.2/28.3
Drinking status
Never 468/537 109/159 23.3/29.6
Ever 197/173 41/46 20.8/26.6
Family history of cancer
No 536/655 121/187 22.6/28.6
Yes 126/55 29/18 22.5/32.7
*Two-sided χ2 test for either genotype distributions or allele frequencies between t
† Adjusted for age, smoking status, drinking status and family history of cancer in loon the severity of PCa, we studied the association be-
tween rs9904341 polymorphism and clinicopathological
characteristics of PCa patients. As shown in Table 4, the
rs9904341 GC/CC genotypes were much more in PCa pa-
tients with PSA value > 20 ng/ml (P = 0.01, adjusted OR =
1.62, 95% CI = 1.12-2.33). However, no association was ob-
served between the evaluated genotypes and subgroups
with clinical stage and Gleason score (all P > 0.05).
Discussion
Currently, the role of SNP rs9904341 in the promoter re-
gion of survivin is studied to make clear of the susceptibil-
ity and manifestation of clinicopathological characteristics04341 G > C polymorphism and risk of PCa
ls) P* Adjusted
OR(95%CI) †GC + CC
n % GC + CC versus
GG
515/505 77.5/71.1 0.008 1.40 (1.09-1.80)
244/257 78.7/72.4 0.060 1.35 (0.93-1.95)
271/248 76.3/69.9 0.052 1.44 (1.02- 2.01)
218/248 77.9/70.2 0.031 1.47 (1.01-2.12)
297/257 77.1/72.0 0.109 1.35 (0.96-1.89)
91/128 71.1/72.3 0.899 0.94 (0.52-1.57)
205/129 79.8/71.7 0.050 1.56 (0.99-2.58)
359/378 76.7/70.4 0.024 1.37 (1.02-1.83)
156/127 79.2/73.4 0.191 1.46 (0.89-2.38)
415/468 77.4/71.4 0.019 1.36 (1.04-1.77)
100/37 77.5/62.3 0.145 1.60 (0.79-3.25)
he cases and controls.
gistic regression model; 95% CI: 95% confidence interval.
Table 4 Associations of the the BIRC5 rs9904341
polymorphisms with the clinicopathological
characteristics of PCa
Variables Genotypes, n (%) P * Adjusted OR (95%CI) *
GG CG + CC CG + CC versus GG
Clinical Stage† 0.260
Localized 94 (24.1) 296 (75.9) 1.00 (reference)
Advanced 56 (20.3) 219 (79.6) 1.23 (0.85-1.79)
Gleason Score 0.534
<7 55 (24.4) 170 (75.6) 1.00 (reference)
=7 51 (23.1) 170 (76.9) 1.10 (0.71-1.71)
>7 44 (20.1) 175 (79.9) 1.26 (0.80-1.98)
PSA(ng /ml) 0.010
≤20 75 (27.6) 197 (72.4) 1.00 (reference)
>20 75 (19.1) 318 (80.9) 1.62 (1.12-2.33)
* The P value and ORs were calculated and adjusted for age, smoking,
drinking, and family history of cancer in logistic regression model; 95% CI: 95%
confidence interval; OR: odds ratio.
†Localized: T1- 2N0M0; Advanced: T3-4NxMx or TxN1Mx or TxNxM1. Clinical staging
according to the international TNM system for PCa.
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tion done so far to evaluate the role of the SNP
(rs9904341) in the survivin gene pertaining to the risk and
progression of PCa.
Our results revealing the association between this
survivin polymorphism and the risk of PCa are biologic-
ally plausible. It is broadly accepted that PCa’s resistance
to apoptosis is associated with an alteration in the ex-
pression of pro-apoptotic [45] and anti-apoptotic protein
[46]. Survivin, as an apoptotic inhibitor, plays a signifi-
cant role in the apoptosis pathway and cell proliferation
[6]. Growing evidence enhanced that survivin was prom-
inently over-expressed in various human cancers [20],
paralleling with the deregulated apoptosis in cancer [7].
With respect to PCa, Krajewska et al. observed that in-
creased IAP (including survivin) expression occured
early in the pathogenesis of PCa [28]. Koike et al. dem-
onstrated that survivin was associated with PCa cell pro-
liferation [29]. In addition, some studies suggested that
survivin made a crucial contribution to apoptotic resist-
ance in PCa either in vitro or in vivo [26,47].
Numerous epidemiological studies, such as case–con-
trol, cohort and genome wide association studies
(GWAS), have exhibited the role of low-risk genetic var-
iants in susceptibility to PCa. In our present research, an
increased risk of PCa was observed among the individ-
uals carrying C allele compared with those carrying G
allele, as evidenced by the data obtained in previous
studies of urothelial carcinoma [39], nasopharyngeal car-
cinoma [33], esophageal cancer [37], colorectal cancer
[40], endometrial cancer [48] and gastric cancer [41].
What mechanism underlies the association between thisSNP and susceptibility of PCa is still not well-known. It
might be safe to suppose that rs9904341 SNP, located at
the binding site for the CDE/CHR repressor in the pro-
moter of survivin, affects transcriptional activity by
modifying the binding motif of the CDE/CHR repressor
which leads to the measurable and functional discrep-
ancy in survivin expression. This supposition has been
vigorously advocated by other investigators. Xu et al.
firstly demonstrated that the presence of mutation in-
cluding rs9904341 polymorphism was correlated with
increased survivin expression at both mRNA and protein
levels in some cell lines [44]. Jang et al. observed that -
31C allele had a significantly higher transcriptional activ-
ity compared with -31G allele in vitro promoter assay
for lung cancer [42]. Nikiteas et al. revealed that mRNA
levels of survivin expressed by homozygous for the -
31CC survivin genotype were approximately 1.6 times
higher than those with the GG/GC genotypes [40].
Habuchi et al. reported that a significantly higher
survivin mRNA and protein expression level was ob-
served in bladder cancer cell with an increased number
of -31C allele by immunohistological evaluation and re-
verse transcriptase-PCR [36]. Taking these observations
into consideration, we assumed that surviving probably
contributed to the susceptibility of PCa, and our finding
confirmed this hypothesis. Moreover, according to the
Hapmap database, there was another polymorphism
rs8073069 in complete linkage disequilibrium with
rs9904341, so we only selected rs9904341 to genotype
and analyze.
It is well known that PCa is a complex malignancy
caused by multifactor: age, gene or environment. In
stratified analyses, we observed that the effect of
rs9904341 polymorphism on the risk of PCa was
overstressed among nondrinkers, nonsmokers and those
without a family history of cancer, indicating that this
polymorphism was an independent risk of PCa and the
interaction of gene-environment might be very weak in
the subgroups. Furthermore, a line of studies have
manifested that the over-expression of survivin was con-
sidered to be a marker for aggressive PCa and signaling
a poor prognosis [30-32]. According to the subgroup
analyses by clinicopathological characteristics, our re-
sults detected that PCa patients having the genotypes
GC/CC were significantly associated with cases whose
PSA value > 20 ng/ml, suggesting that the polymorphism
appeared to play an important role in the progression of
PCa. Our conclusion is compatible with the results of
one previous research by Wang et al., but contradictory
to the conclusions of other studies [36,49-51]. The
discrepancy of these findings may be elucidated by
the diverse molecular mechanisms of carcinogenesis
in tumors, rather merely by the different genetic
background.
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tributions of the survivin polymorphism vary with ethni-
city compared with the published data. In the controls
of our study, the frequencies of GG, GC, CC genotypes
in rs9904341 are 28.9%, 46.6%, 24.5%, respectively,
which is similar to the date derived from some previous
studies on Asian population [36,38,41,42,49], but differ-
ent from the results reported by Bayram and Veress in
European [34,43]. Probably, this difference results from
the genetic discrepancy. Therefore, our findings should
be independently validated in other communities with
high incidence, especially in Caucasian.
Additionally, we are aware of a few limitations in our
study, some of which cannot be overcame . First, -based
on the patients and the control group randomly from
the same hospital, we cannot completely rule out the in-
herent selection bias. Nevertheless, in order to minimize
potential biases, we have made a rigorous epidemio-
logical design of study subjects and more statistical ad-
justments for known risk factors. Second, our study
lacks detailed information including environmental ex-
posure and survival data, and our sample is medium-
sized, which may weaken the statistical power of this
study. Under the current sample size, we have 80%
power at a 0.05 significance level to detect an OR of 1.4
or higher and 0.69 or lower with an exposure frequency
of 24.5%. In addition, our conclusions are in accordance
with the meta analyses (3329 cases and 3979 controls) in
regard to the association between rs9904341 polymorph-
ism and the risk of cancer performed by Mittal [52].
Third, our findings together with other observations
from literature are still in conflict, and the significant as-
sociation between rs9904341 polymorphism and PCa
risk should be interpreted with caution.
Conclusions
In summary, our current results provide the primary evi-
dence that the polymorphism rs9904341 in the promoter
of survivin is a genetic susceptibility factor for the
pathogenesis and progression of PCa in Chinese popula-
tion. The observations of the present study are valuable
to improve our understanding of the role of survivin in
PCa. However, it is necessary that additional studies with
more detailed data on environmental exposure and sur-
vival data of more samples and functional characteriza-
tions are needed to confirm our results, particularly in
PCa.
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